Breast Screening Review Bibliography Bibliography to date - April ...

Breast Screening Review BibliographyBibliography to date - April 2012Please note that this is not an exhaustive or final list.Alexander FE, Anderson TJ et al, 14 years of follow-up from the Edinburgh randomised trialof breast-cancer screening, Lancet, 1999, 353 (9168): 1903-1908Allgood PC, Warwick J, et al A case-control study of the impact of the East Anglian breastscreening programme on breast cancer mortality, British Journal of Cancer, 2004, 11: 1-4Autier P, Boniol M, et al Breast cancer mortality in neighbouring European countries withdifferent levels of screening but similar access to treatment: trend analysis of WHOmortality database, BMJ. 2011, 343: d4411Autier P, Boniol M, La Vecchia C, Vatten L, Gavin A, Héry C, Heanue M, Disparities in breastcancer mortality trends between 30 European countries: retrospective trend analysis ofWHO mortality database. BMJ. 2010 Aug 11;341:c3620.Autier P, Boniol M, Middleton R, Doré JF, Héry C, Zheng T, Gavin A. Advanced breast cancerincidence following population-based mammographic screening. Ann Oncol. 2011Aug;22(8):1726-35.Autier P, Boniol M. The incidence of advanced breast cancer in the West Midlands, UnitedKingdom. Eur J Cancer Prev. 2012 May;21(3):217-21.Autier P, Héry C, Haukka J, Boniol M, Byrnes G. Advanced breast cancer and breast cancermortality in randomized controlled trials on mammography screening. J Clin Oncol. 2009Dec 10;27(35):5919-23Baines CJ, Miller AB, Kopans DB, Moskowitz M, Sanders DE, Sickles EA, To T, Wall C,Canadian National Breast Screening Study: assessment of technical quality by externalreview. AJR Am J Roentgenol. 1990 155(4):743-7Barratt A, Howard K, Irwig L, Salkeld G, Houssami N. Model of outcomes of screeningmammography: information to support informed choices. BMJ. 2005 Apr 23;330(7497):936Baum M, Screening for breast cancer: time for a re-think, BHJM 2012, 73:6-7Beral V, Alexander M, Duffy S et al, The number of women who would need to be screenedregularly by mammography to prevent one death from breast cancer, J Med Screen, 2011,18 (4): 210-212Berry DA, Cronin KA et al, Effect of Screening and Adjuvant Therapy on Mortality fromBreast Cancer, N Eng J Med, 2005, 27:353 (17):1784-921

Blanks RG, Moss SM et al Effect of NHS breast screening programme on mortality frombreast cancer in England and Wales, 1990-8: comparison of observed with predictedmortality, BMJ, 2000, 16;321:665-669Breast Screening Frequency Trial Group. The frequency of breast cancer screening: resultsfrom the UKCCCR Randomised Trial. United Kingdom Co-ordinating Committee on CancerResearch. Eur J Cancer. 2002, 38(11):1458-64.Bulliard JL, Levi F. Mammography screening: time to re-evaluate its impact? Eur J CancerPrev. 2012 Jan 23. [Epub ahead of print]Burton RC, Bell RJ, Thiagarajah G, Stevenson C. Adjuvant therapy, not mammographicscreening, accounts for most of the observed breast cancer specific mortality reductions inAustralian women since the national screening program began in 1991. Breast Cancer ResTreat 2011; 29 Sep [Epub ahead of print].Canadian Task Force on Preventive Health Care, Recommendations on screening for breastcancer in average-risk women aged 40-74 years, CMAJ, 2011, 183 (17): 1991-2001Collaborative Group on Hormonal Factors in Breast Cancer, Familial breast cancer:collaborative reanalysis of individual data from 52 epidemiological studies including 58 209women with breast cancer and 101 986 women without the disease, 2001, The Lancet, 358:1389-1399Collins LC, Tamimi RM, Baer HJ, Connolly JL, Colditz GA, Schnitt SJ. Outcome of patients withductal carcinoma in situ untreated after diagnostic biopsy: results from the Nurses' HealthStudy. Cancer, 2005, 103(9):1778-84Cuzick J, Sestak I, Baum M, Buzdar A, Howell A, Dowsett M, Forbes JF; ATAC/LATTEinvestigators. Effect of anastrozole and tamoxifen as adjuvant treatment for early-stagebreast cancer: 10-year analysis of the ATAC trial. Lancet Oncol. 2010 Dec;11(12):1135-41.Cuzick J, Sestak I, Pinder SE, Ellis IO, Forsyth S, Bundred NJ, Forbes JF, Bishop H, Fentiman IS,George WD. Effect of tamoxifen and radiotherapy in women with locally excised ductalcarcinoma in situ: long-term results from the UK/ANZ DCIS trial. Lancet Oncol. 2011Jan;12(1):21-9.de Gelder R, Fracheboud J. Digital, mammography screening: Weighing reduced mortalityagainst increased overdiagnosis, Prev Med 2011 , 53 (3): 134-140de Gelder R, Heijnsdijk EA et al, Interpreting overdiagnosis estimates in population-basedmammography screening, Epidemiol Reviews, 2011, 33 (1): 111-121De Haes JCJM, de Koning H et al, The impact of a breast cancer screening programme onquality - adjusted life years, Int J Cancer, 1991, 49 (4), 538-5442

De Koning H, van Ineveld B et al, Breast Screening and cost effectiveness: Policy alternatives,quality of life considerations and the possible impact of uncertain factors, Int J Cancer, 1991,49(4), 531 - 537Duffy SW, Agbaje O et al, Overdiagnosis and overtreatment of breast cancer: estimates ofoverdiagnosis from two trials of mammographic screening for breast cancer, BCR, 2005, 7(6): 258-265Duffy SW, Interpretation of the breast screening trials: a commentary on the recent paperby Gøtzsche and Olsen. Breast, 2001, 10(3):209-12.Duffy SW, Lynge E et al, Complexities in the estimation of overdiagnosis in breast cancerscreening, BJC, 2008, 99 (7): 1176-1178Duffy SW, Tabar L et al, Absolute numbers of lives saved and overdiagnosis in breast cancerscreening, from a randomized trial and from the Breast Screening Programme in England, JMed Screen, 2010; 17: 25Duffy SW, Tabar L, Vitak B, Yen MF, Warwick J, Smith RA, Chen HH, The Swedish Two-CountyTrial of mammographic screening: cluster randomisation and end point evaluation. AnnOncol. 2003, 14(8):1196-8.Esserman L, Shieh Y, Thompson I. Rethinking screening for breast cancer and prostatecancer. JAMA. 2009 Oct 21;302(15):1685-92.Esserman L, Thompson I, Solving the overdiagnosis dilemma. J Natl Cancer Inst. 2010 May5;102(9):582-3.Fielder HM, Warwick J, et al A case-control study to estimate the impact on breast cancerdeath of the breast screening programme in Wales, J Med Screen, 2004, 11 (4): 194-198Frachebound J, Groenewould JH et al, Seventy-five years is an appropriate upper age limitfor population-based mammography screening, Int J Cancer, 2006, 118, 2020-2025Freedman DA, Petitti DB, Robins JM , On the efficacy of screening for breast cancer. Int JEpidemiol. 2004 Feb;33(1):43-55.Gabe R, Duffy SW. Evaluation of service screening mammography in practice: the impact onbreast cancer mortality. Ann Oncol. 2005;16 Suppl 2:ii153-62.Gabe R, Tryggvadóttir L, A case-control study to estimate the impact of the Icelandicpopulation-based mammography screening program on breast cancer death, Acta Radiol,2007, 48 (9): 948-955Gelder R de, van As E et al, Breast cancer screening: Evidence for false reassurance? 2008,Int J Cancer, 123, 680-686Giordan L, von Karsa L, Mammographic screening programmes in Europe: organization,coverage and participation, J Med Screen, to be published in 20123

Glasziou P, Houssami N. The evidence base for breast cancer screening. Prev Med 2011; 2Jun [Epub ahead of print].Gøtzsche PC, Jørgensen KJ, Zahl PH, Mæhlen J. Why mammography screening has not livedup to expectations from the randomised trials. Cancer Causes Control. 2012 Jan;23(1):15-21Gøtzsche PC, Jørgensen KJ. The breast screening programme and misinforming the public, JR Soc Med. 2011 Sep;104(9):361-9Gøtzsche PC, Nielsen M. Screening for breast cancer with mammography. CochraneDatabase of Systematic Reviews 2011, Issue 1. Art. No.: CD001877.Gøtzsche PC. Relation between breast cancer mortality and screening effectiveness:systematic review of the mammography trials. Dan Med Bull. 2011 Mar;58(3):A4246Groenewoud JH, Otten JD et al, Cost effectiveness of different reading and referralstrategies in mammography screening in the Netherlands, Breast Cancer Res Treat, 2007,102:211-218Hakama M, Pukkala E et al, Effectiveness of the public health policy for breast cancerscreening in Finland: population based cohort study, BMJ, 1997, 31 4 (7084): 864-867Harris R, Yeatts J et al, Breast cancer screening for women ages 50 to 69 years a systematicreview of observational evidence, 2011, Preventive Medicine, 53 (3): 108-114IARC working group on the evaluation of cancer-preventative strategies, Handbook onBreast Cancer Screening, 2002 (http://www.iarc.fr/en/publications/pdfsonline/prev/index1.php)Jonsson H, Johansson R et al, Increased incidence of invasive breast cancer after theintroduction of service screening with mammography in Sweden, Int J Cancer, 2005, 117(5):842-847Jonsson H, Nyström L et al, Service screening with mammography of women aged 50-69years in Sweden: effects on mortality from breast cancer, J Med Screen, 2001, 8 (3): 152-160Jørgensen KJ Flawed methods explain the effect of mammography screening in Nijmegen. BrJ Cancer. 2011 Aug 9;105(4):592-3Jørgensen KJ, Gøtzsche PC, Overdiagnosis in publicly organised mammography screeningprogrammes: systematic review of incidence trends, BMJ, 2009, 9 (339): 2587Jørgensen KJ, Keen JD, Gøtzsche PC. Is mammographic screening justifiable considering itssubstantial overdiagnosis rate and minor effect on mortality? Radiology. 2011Sep;260(3):621-7.Jørgensen KJ, Zahl PH et al, Breast cancer mortality in organised mammography screening inDenmark: comparative study, BMJ, 2010, 340: 12414

Jørgensen KJ, Zahl PH et al, Overdiagnosis in organised mammography screening inDenmark. A comparative study, BMC Womens Health, 2009, 22 (9): 36Kalager M, Adami HO, Bretthauer M, Tamimi RM. Overdiagnosis of invasive breast cancerdue to mammography screening: results from the norwegian screening program. Ann InternMed. 2012 Apr 3;156(7):491-9.Kalager M, Zelen M et al, Effect of Screening Mammography on Breast-Cancer Mortality inNorway, New Eng J Medicine, 2010, 363 (13): 1203-1210Larsson LG, Nyström L, Wall S, Rutqvist L, Andersson I, Bjurstam N, Fagerberg G, Frisell J,Tabár L. The Swedish randomised mammography screening trials: analysis of their effect onthe breast cancer related excess mortality. J Med Screen. 1996;3(3):129-32.Lynge E, Braaten T, Mammography activity in Norway 1983 to 2008, Acta Oncol, 2011, 50(7): 1-6Malmgren JA, Parikh J, Atwood MK, Kaplan HG. Impact of mammography detection on thecourse of breast cancer in women aged 40-49 years. Radiology. 2012 Mar;262(3):797-806.Martinez-Alonso M, Vilaprinyo E et al, Breast cancer incidence and overdiagnosis inCatalonia (Spain), BCR, 2010, 12 (4): R58McPherson K, Should we screen for breast cancer, 2010, BMJ 341:233Miller AB, Baines CJ et al, Canadian National Breast Screening Study: 1. Breast cancerdetection and death rates among women aged 40 to 49 years, CMAJ, 1992, 147 (10): 1459-1476Miller AB, Baines CJ et al, Canadian National Breast Screening Study: 2. Breast cancerdetection and death rates among women aged 50 to 59 years, CMAJ, 1992, 147 (10): 1477-1488Miller AB, To T, The Canadian National Breast Screening Study-1: breast cancer mortalityafter 11 to 16 years of follow-up. A randomized screening trial of mammography in womenage 40 to 49 years, Ann Intern Med, 2002, 137: 305-312Morrell S, Barratt A et al, Estimates of overdiagnosis of invasive breast cancer associatedwith screening mammography, Cancer Causes Control, 2010 21 (2): 275-282Moss S, Overdiagnosis and overtreatment of breast cancer: overdiagnosis in randomisedcontrolled trials of breast cancer screening, BCR, 2005,7 (5): 230-234Moss SM, Cuckle H et al, Effect of mammographic screening from age 40 years on breastcancer mortality at 10 years' follow-up: a randomised controlled trial, Lancet, 2006, 368(9552): 2053-20605

Nagtegaal ID, Allgood PC, Duffy SW, Kearins O, Sullivan EO, Tappenden N, Wallis M,Lawrence G. Prognosis and pathology of screen-detected carcinomas: how different arethey? Cancer. 2011 Apr 1;117(7):1360-8Nederend J, Duijm LE, Voogd AC, Groenewoud JH, Jansen FH, Louwman MW. Trends inincidence and detection of advanced breast cancer at biennial screening mammography inThe Netherlands: a population based study. Breast Cancer Res. 2012 Jan 9;14(1):R10.Nelson HD, Tyne K et al, Screening for Breast Cancer: An Update for the U.S. PreventiveServices Task Force, Ann Intern Med. 2009;151:727-737.Norman SA, Russell Localio A et al, Protection of mammography screening against deathfrom breast cancer in women aged 40-64 years, Cancer Causes Control, 2007, 18 (9): 909-918Nyström L, Andersson I et al, Long-term effects of mammography screening: updatedoverview of the Swedish randomised trials, Lancet, 2002 359 (9310): 909-919Nyström L, Larsson LG, Rutqvist LE, Lindgren A, Lindqvist M, Rydén S, Andersson I, BjurstamN, Fagerberg G, Frisell J, et al. Determination of cause of death among breast cancer cases inthe Swedish randomized mammography screening trials. A comparison between officialstatistics and validation by an endpoint committee. Acta Oncol. 1995;34(2):145-52Olsen AH, Agbaje OF et al, Overdiagnosis, sojourn time, and sensitivity in the Copenhagenmammography screening program, The Breast Journal, 2006, 12 (24): 338-342Olsen AH, Njor SH, Breast cancer mortality in Copenhagen after introduction ofmammography screening: cohort study, BMJ, 2005, 330:220-Olsson A, Borgquist S, Butt S, Zackrisson S, Landberg G, Manjer J. Tumour-related factorsand prognosis in breast cancer detected by screening. Br J Surg. 2012 99(1):78-87Otten JD, Broeders MJ, Impressive time-related influence of the Dutch screeningprogramme on breast cancer incidence and mortality, 1975-2006, Int J of Cancer, 2008, 123(8): 1929-1934Otto SJ, Fracheboud J et al, Mammography Screening and Risk of Breast Cancer Death: APopulation-Based Case-Control Study, Cancer Epidemiol Biomarkers Prev, 2012, 21 (1): 66-73Otto SJ, Frachebound J et al, Initiation of population-based mammography screening inDutch municipalities and effect on breast-cancer mortality: a systematic review, Lancet,2003, 26:361 (9367):1411-7Paci E, Miccinesi G et al, Estimate of overdiagnosis of breast cancer due to mammographyafter adjustment for lead time. A service screening study in Italy, Brit Cancer Research,2006, 8 (6): R686

Paci E, Warwick J et al, Overdiagnosis in screening: is the increase in breast cancer incidencerates a cause for concern? J Med Screen, 2004, 11 (1): 23-27Peeters PH, Verbeek AL et al, Evaluation of overdiagnosis of breast cancer in screening withmammography: results of the Nijmegen programme, Int J Epidemiol, 1989, 18 (2): 295-299Percy C, Dolman A. Comparison of the coding of death certificates related to cancer in sevencountries. Public Health Rep. 1978 Jul-Aug;93(4):335-50.Puliti D, Miccinesi G, Effectiveness of service screening: a case-control study to assess breastcancer mortality reduction, British Journal of Cancer, 2008, 99: 423-427Puliti D, Zappa M, et al, An estimate of overdiagnosis 15 years after the start ofmammographic screening in Florence, European Journal of Cancer, 2009 45 (18): 3166-3171Reeves GK, Travis RC, Green J et al, Incidence of Breast Cancer and Its Subtypes in Relationto Individual and Multiple Low-Penetrance Genetic Susceptibility Loci, 2010 JAMA 304(4):426-434Reeves GK, Beral V, Green J, Gathani T, Bull D; Million Women Study Collaborators.Hormonal therapy for menopause and breast-cancer risk by histological type: a cohort studyand meta-analysis. Lancet Oncol. 2006 Nov;7(11):910-8.Reeves GK, Pirie K, Green J, Bull D, Beral V; For the Million Women StudyCollaborators.Comparison of the effects of genetic and environmental risk factors on in situand invasive ductal breast cancer. Int J Cancer. 2011 Sep 27. [Epub ahead of print]Rijnsburger AJ, van Oortmarssen GJ et al, Mammography Benefit in the Canadian nationalscreening Study-2: A Model Evaluation, Int J Cancer, 2004 110, 756-762Roder D, Houssami N et al Population screening and intensity of screening are associatedwith reduced breast cancer mortality: evidence of efficacy of mammography screening inAustralia, Breast Cancer research and Treatment, 2008, 108 (3): 409-416Sanders ME, Schuyler PA, Dupont WD, Page DL. The natural history of low-grade ductalcarcinoma in situ of the breast in women treated by biopsy only revealed over 30 years oflong-term follow-up. Cancer. 2005;103(12):2481-4.Seigneurin A, François O et al, Overdiagnosis from non-progressive cancer detected byscreening mammography: stochastic simulation study with calibration to population basedregistry data, BMJ, 2011, 343: d7017Shapiro S, Venet W, Strax P, Venet L, Roeser R. Ten- to fourteen-year effect of screening onbreast cancer mortality. J Natl Cancer Inst. 1982 Aug;69(2):349-55.Smith RA, Duffy SW, Gabe R, Tabar L, Yen AM, Chen TH, The randomized trials of breastcancer screening: what have we learned? Radiol Clin North Am. 2004, 42(5):793-8067

Smith-Bindman R, Chu PW, Miglioretti DL, Sickles EA, Blanks R, Ballard-Barbash R, Bobo JK,Lee NC, Wallis MG, Patnick J, Kerlikowske K. Comparison of screening mammography in theUnited States and the United Kingdom. JAMA. 2003 290(16):2129-37. Erratum in: JAMA.2004 Feb 18;291(7):824.Stefanek ME. Uninformed compliance or informed choice? A needed shift in our approachto cancer screening. J Natl Cancer Inst. 2011;103(24):1821-6Suhrke P, Mæhlen J, Schlichting E, Jørgensen KJ, Gøtzsche PC, Zahl PH. Effect ofmammography screening on surgical treatment for breast cancer in Norway: comparativeanalysis of cancer registry data. BMJ. 2011 Sep 13;343:d4692Swedish Organised Service Screening Evaluation Group, Reduction in breast cancer mortalityfrom organized service screening with mammography: 1. Further confirmation withextended data, Cancer Epidemiol Biomarkers Prevention, 2006, 15 (1): 45-51Tabár L, Vitak B et al, Swedish two-county trial: impact of mammographic screening onbreast cancer mortality during 3 decades, Radiology, 2011, 260 (6): 658-663Taylor R, Morrell S et al Mammography screening and breast cancer mortality in New SouthWales, Australia, Cancer Causes and Control, 2004, 15 (6): 543-550van den Akker-van Marle E, de Koning H et al Reduction in breast cancer mortality due tothe introduction of mass screening in The Netherlands: comparison with the UnitedKingdom, J Med Screen, 1999, 6 (1): 30-34Wald NJ, Murphy P, Major P, Parkes C, Townsend J, Frost C, UKCCCR multicentrerandomised controlled trial of one and two view mammography in breast cancer screening, .BMJ. 1995, 311(7014):1189-93.Waller M, Moss S, The effect of mammographic screening and hormone replacementtherapy use on breast cancer incidence in England and Wales, Cancer Epidemiol BiomarkersPrevention, 2007, 16 (11): 2257-2261Welch HG, Black WC Using autopsy series to estimate the disease "reservoir" for ductalcarcinoma in situ of the breast: how much more breast cancer can we find? Ann Intern Med.1997 Dec 1;127(11):1023-8Welch HG, Black WC. Overdiagnosis in cancer. J Natl Cancer Inst. 2010 May 5;102(9):605-1White E, Miglioretti DL, Yankaskas BC, Geller BM, Rosenberg RD, Kerlikowske K, Saba L,Vacek PM, Carney PA, Buist DS, Oestreicher N, Barlow W, Ballard-Barbash R, Taplin SH.Biennial versus annual mammography and the risk of late-stage breast cancer. J Natl CancerInst. 2004, 96(24):1832-9.Zackrisson S, Andersson I, Rate of over-diagnosis of breast cancer 15 years after end ofMalmö mammographic screening trial: follow-up study, BMJ, 2006, 332 (7543): 689-6928

Zahl PH, Gøtzsche PC, Mæhlen J. Natural history of breast cancers detected in the Swedishmammography screening programme: a cohort study. Lancet Oncol. 2011 Nov;12(12):1118-24.Zahl PH, Maehlen J, The natural history of invasive breast cancers detected by screeningmammography, Arch Intern Med, 2008 168 (21): 2311-2316Zahl PH, Strand BH et al, Incidence of breast cancer in Norway and Sweden duringintroduction of nationwide screening: prospective cohort study, BMJ, 2004 328 (7445): 921-924Zbuk K, Anand SS. Declining incidence of breast cancer after decreased use of hormonereplacementtherapy: magnitude and time lags in different countries. J EpidemiolCommunity Health. 2012 Jan;66(1):1-7Forrest report and related papersHackshaw A, Benefits and harms of mammography screening, BMJ 2012, 344:d8279Forrest P, Breast Cancer Screening Report to the Health Ministers of England, Wales,Scotland and Northern Ireland, 1986Forrest P, Breast cancer: the decision to screen, 1990Raftery J, Chorozoglou M. Possible net harms of breast cancer screening: updated modellingof Forrest report., BMJ. 2011 343:d7627Unpublished papers accepted for publicationBroeders M, Moss S et al, Review of the impact of population-based screening withmammography on breast cancer mortality in Europe, JMS, to be published in 2012Duffy SW Misplaced criticism of breast cancer research, J R Soc Med – (responding toGøtzsche PC, Jørgensen KJ. The breast screening programme and misinforming the public, JR Soc Med. 2011 Sep;104(9):361-9)Duffy SW, Yen Ming-Fen A et al, Long term benefits of breast screening, 2012, in PressBreast Cancer ManagementHofvind S, Ponti A, Patnick J et al. False positive results in mammographic screening forbreast cancer: a literature review and a survey from screening programmes in Europe, JMS,to be published in 2012Moss SM, Nyström L, Jonsson H, Paci E, Lynge E, Njor S, Broeders M for the EuroscreenWorking Group. A review of trend studies to evaluate the impact of mammographyscreening on breast cancer mortality in Europe. JMS, to be published in 2012Puliti D, Duffy S et al, Methodology and Estimate of Overdiagnosis in Breast Cancer ServiceScreening: A Review of the European Studies, JMS, to be published in 2012Yen Ming-Fen A, Duffy SW et al, Long-term incidence of breast cancer by trial arm in onecounty of the Swedish two-county trial of mammographic screening, Cancer, in press 20129

ReportsAdvisory Committee on Breast Cancer Screening, Screening for breast cancer in England:past and future, Publication number 61, 2006National evaluation of breast cancer screening in the Netherlands 1990-2007, Twelfthevaluation report, 2009NHS Breast Screening Programme, Annual Review 2011The Breast Screening Programme, England 2009-10The non-invasive breast cancer report, An analysis of non-invasive breast cancers diagnosedin England from 1 January 2006 to 31 December 2007, NCIN 2011The second all breast cancer report, focussing on inequalities: variation in breast canceroutcomes with deprivation and age, NCIN 2011The Sloane Project, UK prospective audit of screen-detected non-invasive carcinomas andatypical hyperplasias of the breast, Progress Report 2008/2009 and 2009/2010, WMCIU2010Psychological sequelaeAustoker J, Brett J, Women who are recalled for further investigation for breast screening:psychological consequences 3 years after recall and factors affecting re-attendance, J PublicHealth Med. 2001 23(4):292-300Brett J, Austoker J, Ong G. Do women who undergo further investigation for breastscreening suffer adverse psychological consequences? A multi-centre follow-up studycomparing different breast screening result groups five months after their last breastscreening appointment. J Public Health Med. 1998, 20(4):396-403Cockburn J, Staples M, Hurley SF, De Luise T. Psychological consequences of screeningmammography. J Med Screen. 1994 1(1):7-12Gilbert FJ, Cordiner CM, Affleck IR, Hood DB, Mathieson D, Walker LG, Breast screening: thepsychological sequelae of false-positive recall in women with and without a family history ofbreast cancer, Eur J Cancer. 1998, 34(13):2010-4McCann J, Stockton D, Godward S. Impact of false-positive mammography on subsequentscreening attendance and risk of cancer. Breast Cancer Res. 2002;4(5):R11.Ong G, Austoker J. Recalling women for further investigation of breast screening: women'sexperiences at the clinic and afterwards. J Public Health Med. 1997 19(1):29-36InequalitiesEilbert KW, Carroll K, Peach J, Khatoon S, Basnett I, McCulloch N., Approaches to improvingbreast screening uptake: evidence and experience from Tower Hamlets, BJC, 2009, 101,Suppl 2:S64-7.Logan RF, Patnick J, Nickerson C, Coleman L, Rutter MD, von Wagner C; on behalf of theEnglish Bowel Cancer Screening Evaluation Committee. Outcomes of the Bowel CancerScreening Programme (BCSP) in England after the first 1 million tests. Gut 201110

Moser K, Patnick J, Beral V. Inequalities in reported use of breast and cervical screening inGreat Britain: analysis of cross sectional survey data, BMJ. 2009 Jun 16;338:b2025Other cancersSchröder FH, Hugosson J, Roobol MJ, Tammela TL, Ciatto S, Nelen V, Kwiatkowski M, LujanM, Lilja H, Zappa M, Denis LJ, Recker F, Berenguer A, Määttänen L, Bangma CH, Aus G, VillersA, Rebillard X, van der Kwast T, Blijenberg BG, Moss SM, de Koning HJ, Auvinen A; ERSPCInvestigators, Screening and prostate-cancer mortality in a randomized European study. NEngl J Med. 2009 360(13):1320-8.11